Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Total Valuation
Whitehawk Therapeutics has a market cap or net worth of $141.39M. The enterprise value is $105.81M.
Market Cap$141.39M
Enterprise Value$105.81M
Share Statistics
Whitehawk Therapeutics has 47,128,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,128,360
Owned by Insiders26.29%
Owned by Institutions14.24%
Financial Efficiency
Whitehawk Therapeutics’s return on equity (ROE) is -1.21 and return on invested capital (ROIC) is -126.06%.
Return on Equity (ROE)-1.21
Return on Assets (ROA)-0.91
Return on Invested Capital (ROIC)-126.06%
Return on Capital Employed (ROCE)-1.27
Revenue Per Employee649.58K
Profits Per Employee-1.59M
Employee Count40
Asset Turnover0.37
Inventory Turnover10.18
Valuation Ratios
The current PE Ratio of Whitehawk Therapeutics is 22.5. Whitehawk Therapeutics’s PEG ratio is 0.41.
PE Ratio22.5
PS Ratio3.29
PB Ratio1.63
Price to Fair Value1.63
Price to FCF-1.40
Price to Operating Cash Flow-2.19
PEG Ratio0.41
Income Statement
In the last 12 months, Whitehawk Therapeutics had revenue of 25.98M and earned -63.69M in profits. Earnings per share was -2.36.
Revenue25.98M
Gross Profit-28.07M
Operating Income-67.46M
Pretax Income-63.69M
Net Income-63.69M
EBITDA-64.63M
Earnings Per Share (EPS)-2.36
Cash Flow
In the last 12 months, operating cash flow was -95.25M and capital expenditures -738.00K, giving a free cash flow of -95.99M billion.
Operating Cash Flow-95.25M
Free Cash Flow-95.99M
Free Cash Flow per Share-2.04
Dividends & Yields
Whitehawk Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change12.13%
50-Day Moving Average2.69
200-Day Moving Average2.14
Relative Strength Index (RSI)61.83
Average Volume (3m)3.35M
Important Dates
Whitehawk Therapeutics upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Whitehawk Therapeutics as a current ratio of 3.59, with Debt / Equity ratio of 0.00%
Current Ratio3.59
Quick Ratio3.28
Debt to Market Cap0.00
Net Debt to EBITDA0.43
Interest Coverage Ratio-438.04
Taxes
In the past 12 months, Whitehawk Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Whitehawk Therapeutics EV to EBITDA ratio is -0.89, with an EV/FCF ratio of -0.94.
EV to Sales2.22
EV to EBITDA-0.89
EV to Free Cash Flow-0.94
EV to Operating Cash Flow-0.97
Balance Sheet
Whitehawk Therapeutics has $162.60M in cash and marketable securities with $0.00 in debt, giving a net cash position of $162.60M billion.
Cash & Marketable Securities$162.60M
Total Debt$0.00
Net Cash$162.60M
Net Cash Per Share$3.45
Tangible Book Value Per Share$1.94
Margins
Gross margin is -10.55%, with operating margin of -259.62%, and net profit margin of -245.13%.
Gross Margin-10.55%
Operating Margin-259.62%
Pretax Margin-245.13%
Net Profit Margin-245.13%
EBITDA Margin-248.73%
EBIT Margin-249.47%
Analyst Forecast
The average price target for Whitehawk Therapeutics is $6.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.50
Price Target Upside113.11% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-42.62%
EPS Growth Forecast―